| Literature DB >> 26893906 |
Anne K Penttilä1, Ari Rouhiainen2,3, Leena Kylänpää1, Harri Mustonen1, Pauli Puolakkainen1,4, Heikki Rauvala2, Heikki Repo5.
Abstract
BACKGROUND: The components of nucleosomes, which contain DNA and histones, are released into the circulation from damaged cells and can promote inflammation. We studied whether the on-admission levels of circulating nucleosomes predict the development of severe acute pancreatitis (AP), in particular among the patients who present without clinical signs of organ dysfunction.Entities:
Keywords: Biomarkers; Cellular damage; Nucleosomes; Organ dysfunction; Pancreatitis
Year: 2016 PMID: 26893906 PMCID: PMC4758106 DOI: 10.1186/s40560-016-0135-6
Source DB: PubMed Journal: J Intensive Care ISSN: 2052-0492
Fig. 1Flow chart of the patients. Patients’ classification according to admission modified marshall score (MMS) and patients’ outcome according to the revised Atlanta criteria [1]. OD organ dysfunction, AP acute pancreatitis
Baseline characteristics of patients
| Variable | Mild | Moderately severe | Severe |
|---|---|---|---|
| ( | ( | ( | |
| Male sex, (%) | 15 (65) | 19 (70) | 23 (96) |
| Age (years) | 44 (37–64) | 52 (44–61) | 43 (37–51) |
| Etiology of acute pancreatitis, (%) | |||
| Alcohol | 13 (57) | 20 (74) | 21 (88) |
| Biliary | 6 (26) | 7 (26) | 1 (4) |
| Idiopathic or other | 4 (17) | 0 | 2 (8) |
| Duration of symptoms (hr) | 24 (12–60) | 24 (12–48) | 24 (12–48) |
| CRP on admission (mg/L) | 8 (5–17) | 84 (9–231) | 109 (15–292) |
| Creatinine on admission (μmol/L) | 59 (49–68) | 61 (53–101) | 92 (66–243) |
| APACHE II | 6 (1–7) | 8 (5–10) | 8 (6–15) |
| SOFA on admission | 0 (0–1) | 1 (1–3) | 4 (1–6) |
| MMS on admission | 0 (0–1) | 1 (0–4) | 1 (1–4) |
| MMS < 2 on admission, (%) | 23 (100) | 21 (78) | 14 (58) |
| MMS ≥ 2 on admission, (%) | 0 | 6 (22) | 10 (42) |
| Mechanical invasive ventilation, (%) | 0 | 1 (4) | 22 (92) |
| Haemodialysis, (%) | 0 | 0 | 16 (67) |
| Length of hospital stay (days) | 4 (3–6) | 11 (9–15) | 28 (17–35) |
| Mortality, (%) | 0 | 1 (4) | 7 (29) |
All numerical data are median (interquartile range) or number (%). APACHE II was determined using the most abnormal value for each physiological variable within 24 h of admission to the hospital
APACHE acute physiology and chronic health evaluation, CRP C-reactive protein, MMS modified marshall score, SOFA sepsis-related organ failure assessment score
The levels of circulating nucleosomes on admission in relation to the severity of acute pancreatitis and among survivors and non-survivors
| Nucleosome level (AU) | |
|---|---|
| Mild | 0.005 (0.002–0.14) |
| Moderately severe | 0.09 (0.03–0.32) |
| Severe | 0.30 (0.18–0.45) |
|
| |
| Survivors | 0.09 (0.02–0.27) |
| Non-survivors | 0.38 (0.19–0.77) |
|
|
All numerical data are median (interquartile range)
AU absorbance unit
aJonckheere-Terpstra for trend
bMann-Whitney U test
Fig. 2Receiver-operating characteristic curves of circulating nucleosomes, C-reactive protein (CRP) and creatinine for the prediction of severe acute pancreatitis among a all patients (n = 74), b patients with moderately severe or severe acute pancreatitis (n = 51), and c patients with modified marshall score <2 on admission (n = 58). Arrows point to clinically optimal cutoff points used to calculate the statistical parameters of each biomarker for Table 4
Performance of circulating nucleosomes, C-reactive protein, and creatinine in predicting severe acute pancreatitis
| Cutoff | AUC | Sensitivity | Specificity | +LR | −LR | DOR | |
|---|---|---|---|---|---|---|---|
| All patients ( | |||||||
| Nucleosomes | ≥0.57 AU | 0.718 | 0.21 | 0.96 | 5.2 | 0.83 | 6.3 |
| (0.578–0.858) | (0.09–0.40) | (0.87–0.99) | (1.1–24.9) | (0.67–1.02) | (1.1–35.4) | ||
| CRP | ≥264 mg/L | 0.673 | 0.33 | 0.91 | 3.8 | 0.73 | 5.2 |
| (0.583–0.807) | (0.18–0.53) | (0.81–0.96) | (1.4–10.4) | (0.55–0.98) | (1.5–18.1) | ||
| Creatinine | ≥110 μmol/L | 0.770 | 0.46 | 0.91 | 5.2 | 0.59 | 8.8 |
| (0.654–0.886) | (0.28–0.65) | (0.81–0.96) | (2.0–13.4) | (0.41–0.87) | (2.6–29.8) | ||
| Moderately severe and severe AP patients ( | |||||||
| Nucleosomes | ≥0.57 AU | 0.661 | 0.21 | 0.95 | 2.8 | 0.86 | 3.3 |
| (0.502–0.821) | (0.09–0.40) | (0.77–0.98) | (0.6–13.2) | (0.68–1.08) | (0.6–18.8) | ||
| CRP | ≥386 mg/L | 0.550 | 0.08 | 0.96 | 2.3 | 0.95 | 2.4 |
| (0.390–0.710) | (0.02–0.26) | (0.82–0.99) | (0.2–23.3) | (0.83–1.10) | (0.2–27.9) | ||
| Creatinine | ≥287 μmol/L | 0.717 | 0.21 | 0.96 | 5.6 | 0.82 | 6.8 |
| (0.576–0.858) | (0.09–0.41) | (0.82–0.99) | (0.71–44.8) | (0.66–1.02) | (0.7–63.4) | ||
| Patients with modified marshall score <2 on admission ( | |||||||
| Nucleosomes | ≥0.39 AU | 0.648 | 0.29 | 0.93 | 4.2 | 0.77 | 5.5 |
| (0.443–0.852) | (0.12–0.55) | (0.82–0.98) | (1.1–16.5) | (0.55–1.08) | (1.1–28.4) | ||
| CRP | ≥227 mg/L | 0.539 | 0.14 | 0.92 | 1.8 | 0.93 | 2.0 |
| (0.362–0.716) | (0.04–0.40) | (0.82–0.97) | (0.37–8.9) | (0.74–1.17) | (0.3–12.0) | ||
| Creatinine | ≥139 μmol/L | 0.670 | 0.14 | 0.98 | 7.3 | 0.87 | 8.3 |
| (0.512–0.829) | (0.04–0.40) | (0.90–1.0) | (0.7–74.6) | (0.70–1.09) | (0.7–99.7) | ||
95 % confidence intervals are given in parentheses
AU absorbance unit, AUC area under the curve, CRP C-reactive protein, DOR diagnostic odds ratio, LR likelihood ratio
Univariate and multivariate analysis of circulating nucleosomes, C-reactive protein, and creatinine in predicting severe acute pancreatitis
| OR | 95 % CI |
| |
|---|---|---|---|
| All patients ( | |||
| Univariate analysis | |||
| Age (year) | 0.981 | 0.948–1.015 | 0.273 |
| Male gender | 10.824 | 1.341–87.370 | 0.025 |
| Nucleosomes (AU) | 15.086 | 1.785–127.501 | 0.0127 |
| CRP (mg/L) | 1.004 | 1.000–1.008 | 0.045 |
| Creatinine (μmol/L) | 1.010 | 1.003–1.017 | 0.005 |
| Nucleosomes ≥0.57 AU | 6.316 | 1.127–35.402 | 0.036 |
| CRP ≥264 mg/L | 4.500 | 1.283–15.778 | 0.019 |
| Creatinine ≥110 μmol/L | 7.615 | 2.239–25.900 | 0.001 |
| Multivariate analysis | |||
| Male gender | 8.204 | 0.968–69.511 | 0.054 |
| Creatinine ≥110 μmol/L | 6.180 | 1.742–21.925 | 0.005 |
| Patients with moderately severe or severe acute pancreatitis ( | |||
| Univariate analysis | |||
| Age (year) | 0.974 | 0.936–1.014 | 0.207 |
| Male gender | 9.684 | 1.110–84.465 | 0.040 |
| Nucleosomes (AU) | 5.602 | 0.739–42.474 | 0.095 |
| CRP (mg/L) | 1.001 | 0.997–1.005 | 0.579 |
| Creatinine (μmol/L) | 1.007 | 1.000–1.013 | 0.052 |
| Nucleosomes ≥0.57 AU | 3.289 | 0.575–18.834 | 0.181 |
| CRP ≥386 mg/L | 2.364 | 0.201–27.852 | 0.494 |
| Creatinine ≥287 μmol/L | 6.842 | 0.738–63.442 | 0.091 |
| Multivariate analysis | |||
| Male gender | 9.684 | 1.110–84.465 | 0.040 |
| Patients with modified marshall score <2 on admission ( | |||
| Univariate analysis | |||
| Age (year) | 0.976 | 0.936–1.017 | 0.252 |
| Male gender | 6.724 | 0.801–56.432 | 0.079 |
| Nucleosomes (AU) | 33.070 | 1.216–899.485 | 0.038 |
| CRP (mg/L) | 1.000 | 0.993–1.006 | 0.883 |
| Creatinine (μmol/L) | 1.017 | 0.998–1.036 | 0.088 |
| Nucleosomes ≥0.39 AU | 5.467 | 1.051–28.432 | 0.043 |
| CRP ≥ 227 mg/L | 1.667 | 0.271–10.244 | 0.581 |
| Creatinine ≥139 μmol/L | 7.167 | 0.598–85.946 | 0.120 |
| Multivariate analysis | |||
| Male gender | 6.048 | 0.693–52.799 | 0.104 |
| Nucleosomes (AU) | 33.070 | 1.216–899.485 | 0.038 |
AU absorbance unit, CRP C-reactive protein, OR odds ratio
Admission levels of circulating nucleosomes, C-reactive protein, and creatinine of the patients who presented with organ dysfunction (MMS ≥ 2)
| Variable | Transient OD ( | Persistent OD ( |
|
|---|---|---|---|
| Nucleosomes (AU) | 0.41 (0.18–0.71) | 0.39 (0.24–0.75) | 0.635 |
| CRP (mg/L) | 234 (79–325) | 297 (222–340) | 0.562 |
| Creatinine (μmol/L) | 163 (60–291) | 269 (156-390) | 0.118 |
All numerical data are median (interquartile range)
AU absorbance unit, CRP C-reactive protein, MMS modified marshall score, OD organ dysfunction
aMann-Whitney U test